文献速递前列腺癌

SPARTAN和TITAN试验中晚期前列腺癌患者快速且深度前列腺特异性抗原下降与患者报告健康相关生活质量的析因分析

Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-12-09

该析因分析基于SPARTAN和TITAN试验的患者报告结局数据,评估阿帕他胺联合雄激素剥夺治疗(ADT)后3个月和6个月快速深度PSA下降与生活质量恶化的关联。结果显示,达到深度PSA下降的患者在FACT-P总分、身体健康状况、最严重疼痛强度和最严重疲劳强度等方面恶化时间更长。

要点

  • 阿帕他胺联合ADT治疗3个月时达到深度PSA下降与FACT-P总分恶化时间延长相关。
  • 深度PSA下降患者的最严重疼痛强度和最严重疲劳强度恶化时间亦延长。
  • 6个月PSA下降结果与3个月结果相似。

核心结论

  • 阿帕他胺联合ADT治疗3个月时达到快速且深度PSA下降与nmCRPC和mCSPC患者总体健康相关生活质量和身体健康的更长时间保持相关。

研究设计与样本

  • SPARTAN和TITAN试验患者报告结局数据的析因分析。
  • SPARTAN纳入806例阿帕他胺治疗患者,TITAN纳入525例阿帕他胺治疗患者。
  • 干预为阿帕他胺对比安慰剂联合同期ADT。

主要发现

  • SPARTAN中阿帕他胺治疗患者中位治疗持续时间为32.9个月,TITAN中为39.3个月。
  • 3个月时达到深度PSA下降的患者FACT-P总分、FACT-P身体健康状况、BPI-SF最严重疼痛强度或BFI最严重疲劳强度的恶化时间更长。
  • 6个月PSA下降结果与3个月结果相似。

关键数值与推荐

  • 深度PSA下降定义为PSA≤0.2 ng/ml或较基线下降≥90%。
  • 快速PSA下降定义为治疗3个月和6个月时达到上述标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 应考虑临床研究中患者特征的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adding apalutamide to androgen-deprivation therapy (ADT) resulted in a rapid (at 3- and 6-mo treatment) and deep prostate-specific antigen (PSA) decline (to ≤0.2 ng/ml or ≥90% from baseline), improved overall survival, reduced risk of disease progression, and prolonged health-related quality of life (HRQoL) in nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN and metastatic castration-sensitive PC (mCSPC) in TITAN. OBJECTIVE: To evaluate the association of a rapid, deep PSA decline at 3 and 6 mo achieved with the addition of apalutamide to ADT with patient-reported outcomes (PROs) in SPARTAN and TITAN. DESIGN, SETTING, AND PARTICIPANTS: A post hoc analysis of SPARTAN and TITAN PRO data was performed. INTERVENTION: Apalutamide versus placebo plus concurrent ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PROs were assessed using Functional Assessment of Cancer Therapy-Prostate (FACT-P; SPARTAN and TITAN), Brief Pain Inventory-Short Form (BPI-SF; TITAN), and Brief Fatigue Inventory (BFI; TITAN) at baseline, prespecified cycles during treatment, and after progression for ≤1 yr. The association between a deep PSA decline at landmark 3 or 6 mo of apalutamide and the time to worsening of PROs was assessed using the Kaplan-Meier methodology and Cox proportional-hazard modeling. RESULTS AND LIMITATIONS: Among 806 SPARTAN and 525 TITAN apalutamide-treated patients, the median treatment duration was 32.9 and 39.3 mo, respectively. Patients achieving a deep PSA decline at 3 mo had longer time to worsening in FACT-P total, FACT-P physical well-being, BPI-SF worst pain intensity, or BFI worst fatigue intensity. The 6-mo PSA decline results were similar. Limitations of patient characteristics in clinical studies should be considered. CONCLUSIONS: Attaining a deep and rapid PSA decline at 3 mo with apalutamide plus ADT was associated with longer preservation of overall HRQoL and physical well-being in nmCRPC and mCSPC. PATIENT SUMMARY: Quality of life is maintained in individuals with advanced prostate cancer who achieve a deep prostate-specific antigen decline at 3 mo of apalutamide plus drugs that lower male sex hormones.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Small EJ, Chi KN, Chowdhury S, et al. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer. Eur Urol Oncol. 2023. PMID: 38072759. doi:10.1016/j.euo.2023.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。